

Global Duchenne Muscular Dystrophy Market Growth 2025-2031

<https://marketpublishers.com/r/G64DA9E4FAAEN.html>

Date: January 2025

Pages: 95

Price: US\$ 3,660.00 (Single User License)

ID: G64DA9E4FAAEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Duchenne Muscular Dystrophy market size is predicted to grow from US\$ 2218 million in 2025 to US\$ 19500 million in 2031; it is expected to grow at a CAGR of 43.7% from 2025 to 2031.

Duchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

LP Information, Inc. (LPI) ' newest research report, the "Duchenne Muscular Dystrophy Industry Forecast" looks at past sales and reviews total world Duchenne Muscular

Dystrophy sales in 2024, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy sales for 2025 through 2031. With Duchenne Muscular Dystrophy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Duchenne Muscular Dystrophy industry.

This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Duchenne Muscular Dystrophy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy.

This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Exondys 51

Emflaza

Translarna

Segmentation by Application:

Hospitals

Clinics

Home Care

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Duchenne Muscular Dystrophy market?

What factors are driving Duchenne Muscular Dystrophy market growth, globally and by

region?

Which technologies are poised for the fastest growth by market and region?

How do Duchenne Muscular Dystrophy market opportunities vary by end market size?

How does Duchenne Muscular Dystrophy break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Duchenne Muscular Dystrophy Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Duchenne Muscular Dystrophy by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Duchenne Muscular Dystrophy by Country/Region, 2020, 2024 & 2031
- 2.2 Duchenne Muscular Dystrophy Segment by Type
 - 2.2.1 Exondys
 - 2.2.2 Emflaza
 - 2.2.3 Translarna
- 2.3 Duchenne Muscular Dystrophy Sales by Type
 - 2.3.1 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2020-2025)
- 2.4 Duchenne Muscular Dystrophy Segment by Application
 - 2.4.1 Hospitals
 - 2.4.2 Clinics
 - 2.4.3 Home Care
- 2.5 Duchenne Muscular Dystrophy Sales by Application
 - 2.5.1 Global Duchenne Muscular Dystrophy Sale Market Share by Application (2020-2025)
 - 2.5.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Application (2020-2025)

2.5.3 Global Duchenne Muscular Dystrophy Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Duchenne Muscular Dystrophy Breakdown Data by Company

3.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Company (2020-2025)

3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Company (2020-2025)

3.2 Global Duchenne Muscular Dystrophy Annual Revenue by Company (2020-2025)

3.2.1 Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025)

3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2025)

3.3 Global Duchenne Muscular Dystrophy Sale Price by Company

3.4 Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Duchenne Muscular Dystrophy Product Location Distribution

3.4.2 Players Duchenne Muscular Dystrophy Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR DUCHENNE MUSCULAR DYSTROPHY BY GEOGRAPHIC REGION

4.1 World Historic Duchenne Muscular Dystrophy Market Size by Geographic Region (2020-2025)

4.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Geographic Region (2020-2025)

4.1.2 Global Duchenne Muscular Dystrophy Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic Duchenne Muscular Dystrophy Market Size by Country/Region (2020-2025)

4.2.1 Global Duchenne Muscular Dystrophy Annual Sales by Country/Region (2020-2025)

4.2.2 Global Duchenne Muscular Dystrophy Annual Revenue by Country/Region (2020-2025)

4.3 Americas Duchenne Muscular Dystrophy Sales Growth

- 4.4 APAC Duchenne Muscular Dystrophy Sales Growth
- 4.5 Europe Duchenne Muscular Dystrophy Sales Growth
- 4.6 Middle East & Africa Duchenne Muscular Dystrophy Sales Growth

5 AMERICAS

- 5.1 Americas Duchenne Muscular Dystrophy Sales by Country
 - 5.1.1 Americas Duchenne Muscular Dystrophy Sales by Country (2020-2025)
 - 5.1.2 Americas Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
- 5.2 Americas Duchenne Muscular Dystrophy Sales by Type (2020-2025)
- 5.3 Americas Duchenne Muscular Dystrophy Sales by Application (2020-2025)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Duchenne Muscular Dystrophy Sales by Region
 - 6.1.1 APAC Duchenne Muscular Dystrophy Sales by Region (2020-2025)
 - 6.1.2 APAC Duchenne Muscular Dystrophy Revenue by Region (2020-2025)
- 6.2 APAC Duchenne Muscular Dystrophy Sales by Type (2020-2025)
- 6.3 APAC Duchenne Muscular Dystrophy Sales by Application (2020-2025)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Duchenne Muscular Dystrophy by Country
 - 7.1.1 Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025)
 - 7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025)
- 7.2 Europe Duchenne Muscular Dystrophy Sales by Type (2020-2025)
- 7.3 Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025)
- 7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Duchenne Muscular Dystrophy by Country

8.1.1 Middle East & Africa Duchenne Muscular Dystrophy Sales by Country
(2020-2025)

8.1.2 Middle East & Africa Duchenne Muscular Dystrophy Revenue by Country
(2020-2025)

8.2 Middle East & Africa Duchenne Muscular Dystrophy Sales by Type (2020-2025)

8.3 Middle East & Africa Duchenne Muscular Dystrophy Sales by Application
(2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy

10.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy

10.4 Industry Chain Structure of Duchenne Muscular Dystrophy

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Duchenne Muscular Dystrophy Distributors

11.3 Duchenne Muscular Dystrophy Customer

12 WORLD FORECAST REVIEW FOR DUCHENNE MUSCULAR DYSTROPHY BY GEOGRAPHIC REGION

12.1 Global Duchenne Muscular Dystrophy Market Size Forecast by Region

12.1.1 Global Duchenne Muscular Dystrophy Forecast by Region (2026-2031)

12.1.2 Global Duchenne Muscular Dystrophy Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Duchenne Muscular Dystrophy Forecast by Type (2026-2031)

12.7 Global Duchenne Muscular Dystrophy Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Sarepta Therapeutics

13.1.1 Sarepta Therapeutics Company Information

13.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications

13.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 Sarepta Therapeutics Main Business Overview

13.1.5 Sarepta Therapeutics Latest Developments

13.2 PTC Therapeutics

13.2.1 PTC Therapeutics Company Information

13.2.2 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications

13.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)

13.2.4 PTC Therapeutics Main Business Overview

13.2.5 PTC Therapeutics Latest Developments

13.3 Pfizer

13.3.1 Pfizer Company Information

13.3.2 Pfizer Duchenne Muscular Dystrophy Product Portfolios and Specifications

13.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin

(2020-2025)

13.3.4 Pfizer Main Business Overview

13.3.5 Pfizer Latest Developments

13.4 Bristol-Myers Squibb

13.4.1 Bristol-Myers Squibb Company Information

13.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolios and Specifications

13.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)

13.4.4 Bristol-Myers Squibb Main Business Overview

13.4.5 Bristol-Myers Squibb Latest Developments

13.5 Italfarmaco

13.5.1 Italfarmaco Company Information

13.5.2 Italfarmaco Duchenne Muscular Dystrophy Product Portfolios and Specifications

13.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)

13.5.4 Italfarmaco Main Business Overview

13.5.5 Italfarmaco Latest Developments

13.6 Santhera Pharmaceuticals

13.6.1 Santhera Pharmaceuticals Company Information

13.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolios and Specifications

13.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2025)

13.6.4 Santhera Pharmaceuticals Main Business Overview

13.6.5 Santhera Pharmaceuticals Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Duchenne Muscular Dystrophy Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Duchenne Muscular Dystrophy Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Exondys 51

Table 4. Major Players of Emflaza

Table 5. Major Players of Translarna

Table 6. Global Duchenne Muscular Dystrophy Sales by Type (2020-2025) & (K Doses)

Table 7. Global Duchenne Muscular Dystrophy Sales Market Share by Type
(2020-2025)

Table 8. Global Duchenne Muscular Dystrophy Revenue by Type (2020-2025) & (\$ million)

Table 9. Global Duchenne Muscular Dystrophy Revenue Market Share by Type
(2020-2025)

Table 10. Global Duchenne Muscular Dystrophy Sale Price by Type (2020-2025) & (USD/Dose)

Table 11. Global Duchenne Muscular Dystrophy Sale by Application (2020-2025) & (K Doses)

Table 12. Global Duchenne Muscular Dystrophy Sale Market Share by Application
(2020-2025)

Table 13. Global Duchenne Muscular Dystrophy Revenue by Application (2020-2025) & (\$ million)

Table 14. Global Duchenne Muscular Dystrophy Revenue Market Share by Application
(2020-2025)

Table 15. Global Duchenne Muscular Dystrophy Sale Price by Application (2020-2025) & (USD/Dose)

Table 16. Global Duchenne Muscular Dystrophy Sales by Company (2020-2025) & (K Doses)

Table 17. Global Duchenne Muscular Dystrophy Sales Market Share by Company
(2020-2025)

Table 18. Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025) & (\$ millions)

Table 19. Global Duchenne Muscular Dystrophy Revenue Market Share by Company
(2020-2025)

Table 20. Global Duchenne Muscular Dystrophy Sale Price by Company (2020-2025) & (USD/Dose)

Table 21. Key Manufacturers Duchenne Muscular Dystrophy Producing Area
Distribution and Sales Area

Table 22. Players Duchenne Muscular Dystrophy Products Offered

Table 23. Duchenne Muscular Dystrophy Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Duchenne Muscular Dystrophy Sales by Geographic Region
(2020-2025) & (K Doses)

Table 27. Global Duchenne Muscular Dystrophy Sales Market Share Geographic Region (2020-2025)

Table 28. Global Duchenne Muscular Dystrophy Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region (2020-2025)

Table 30. Global Duchenne Muscular Dystrophy Sales by Country/Region (2020-2025) & (K Doses)

Table 31. Global Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2020-2025)

Table 32. Global Duchenne Muscular Dystrophy Revenue by Country/Region (2020-2025) & (\$ millions)

Table 33. Global Duchenne Muscular Dystrophy Revenue Market Share by Country/Region (2020-2025)

Table 34. Americas Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)

Table 35. Americas Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2025)

Table 36. Americas Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (\$ millions)

Table 37. Americas Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)

Table 38. Americas Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 39. APAC Duchenne Muscular Dystrophy Sales by Region (2020-2025) & (K Doses)

Table 40. APAC Duchenne Muscular Dystrophy Sales Market Share by Region (2020-2025)

Table 41. APAC Duchenne Muscular Dystrophy Revenue by Region (2020-2025) & (\$ millions)

Table 42. APAC Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)

Table 43. APAC Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 44. Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)

Table 45. Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (\$ millions)

Table 46. Europe Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)

Table 47. Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 48. Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)

Table 49. Middle East & Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)

Table 50. Middle East & Africa Duchenne Muscular Dystrophy Sales byType (2020-2025) & (K Doses)

Table 51. Middle East & Africa Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 52. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy

Table 53. Key Market Challenges & Risks of Duchenne Muscular Dystrophy

Table 54. Key IndustryTrends of Duchenne Muscular Dystrophy

Table 55. Duchenne Muscular Dystrophy Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Duchenne Muscular Dystrophy Distributors List

Table 58. Duchenne Muscular Dystrophy Customer List

Table 59. Global Duchenne Muscular Dystrophy SalesForecast by Region (2026-2031) & (K Doses)

Table 60. Global Duchenne Muscular Dystrophy RevenueForecast by Region (2026-2031) & (\$ millions)

Table 61. Americas Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)

Table 62. Americas Duchenne Muscular Dystrophy Annual RevenueForecast by Country (2026-2031) & (\$ millions)

Table 63. APAC Duchenne Muscular Dystrophy SalesForecast by Region (2026-2031) & (K Doses)

Table 64. APAC Duchenne Muscular Dystrophy Annual RevenueForecast by Region (2026-2031) & (\$ millions)

Table 65. Europe Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)

Table 66. Europe Duchenne Muscular Dystrophy RevenueForecast by Country (2026-2031) & (\$ millions)

Table 67. Middle East & Africa Duchenne Muscular Dystrophy SalesForecast by Country (2026-2031) & (K Doses)

Table 68. Middle East & Africa Duchenne Muscular Dystrophy RevenueForecast by Country (2026-2031) & (\$ millions)

Table 69. Global Duchenne Muscular Dystrophy SalesForecast byType (2026-2031) & (K Doses)

Table 70. Global Duchenne Muscular Dystrophy RevenueForecast byType (2026-2031) & (\$ millions)

Table 71. Global Duchenne Muscular Dystrophy SalesForecast by Application (2026-2031) & (K Doses)

Table 72. Global Duchenne Muscular Dystrophy RevenueForecast by Application (2026-2031) & (\$ millions)

Table 73. SareptaTherapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors

Table 74. SareptaTherapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications

Table 75. SareptaTherapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 76. SareptaTherapeutics Main Business

Table 77. SareptaTherapeutics Latest Developments

Table 78. PTCTherapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors

Table 79. PTCTherapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications

Table 80. PTCTherapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 81. PTCTherapeutics Main Business

Table 82. PTCTherapeutics Latest Developments

Table 83. Pfizer Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors

Table 84. Pfizer Duchenne Muscular Dystrophy Product Portfolios and Specifications

Table 85. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 86. Pfizer Main Business

Table 87. Pfizer Latest Developments

Table 88. Bristol-Myers Squibb Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors

Table 89. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolios and Specifications

Table 90. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 91. Bristol-Myers Squibb Main Business

Table 92. Bristol-Myers Squibb Latest Developments

Table 93. Italfarmaco Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors

Table 94. Italfarmaco Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 95. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Italfarmaco Main Business
Table 97. Italfarmaco Latest Developments
Table 98. Santhera Pharmaceuticals Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 99. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolios and Specifications
Table 100. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Santhera Pharmaceuticals Main Business
Table 102. Santhera Pharmaceuticals Latest Developments

LIST OFFIGURES

Figure 1. Picture of Duchenne Muscular Dystrophy
Figure 2. Duchenne Muscular Dystrophy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Duchenne Muscular Dystrophy Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Duchenne Muscular Dystrophy Revenue Growth Rate 2020-2031 (\$ millions)
Figure 8. Duchenne Muscular Dystrophy Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
Figure 9. Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2024)
Figure 10. Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Exondys 51
Figure 12. Product Picture of Emflaza
Figure 13. Product Picture of Translarna
Figure 14. Global Duchenne Muscular Dystrophy Sales Market Share by Type in 2025
Figure 15. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2020-2025)

- Figure 16. Duchenne Muscular Dystrophy Consumed in Hospitals
- Figure 17. Global Duchenne Muscular Dystrophy Market: Hospitals (2020-2025) & (K Doses)
- Figure 18. Duchenne Muscular Dystrophy Consumed in Clinics
- Figure 19. Global Duchenne Muscular Dystrophy Market: Clinics (2020-2025) & (K Doses)
- Figure 20. Duchenne Muscular Dystrophy Consumed in Home Care
- Figure 21. Global Duchenne Muscular Dystrophy Market: Home Care (2020-2025) & (K Doses)
- Figure 22. Global Duchenne Muscular Dystrophy Sale Market Share by Application (2024)
- Figure 23. Global Duchenne Muscular Dystrophy Revenue Market Share by Application in 2025
- Figure 24. Duchenne Muscular Dystrophy Sales by Company in 2025 (K Doses)
- Figure 25. Global Duchenne Muscular Dystrophy Sales Market Share by Company in 2025
- Figure 26. Duchenne Muscular Dystrophy Revenue by Company in 2025 (\$ millions)
- Figure 27. Global Duchenne Muscular Dystrophy Revenue Market Share by Company in 2025
- Figure 28. Global Duchenne Muscular Dystrophy Sales Market Share by Geographic Region (2020-2025)
- Figure 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region in 2025
- Figure 30. Americas Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
- Figure 31. Americas Duchenne Muscular Dystrophy Revenue 2020-2025 (\$ millions)
- Figure 32. APAC Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
- Figure 33. APAC Duchenne Muscular Dystrophy Revenue 2020-2025 (\$ millions)
- Figure 34. Europe Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
- Figure 35. Europe Duchenne Muscular Dystrophy Revenue 2020-2025 (\$ millions)
- Figure 36. Middle East & Africa Duchenne Muscular Dystrophy Sales 2020-2025 (K Doses)
- Figure 37. Middle East & Africa Duchenne Muscular Dystrophy Revenue 2020-2025 (\$ millions)
- Figure 38. Americas Duchenne Muscular Dystrophy Sales Market Share by Country in 2025
- Figure 39. Americas Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)
- Figure 40. Americas Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)

Figure 41. Americas Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 42. United States Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 43. Canada Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 44. Mexico Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 45. Brazil Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 46. APAC Duchenne Muscular Dystrophy Sales Market Share by Region in 2025

Figure 47. APAC Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2025)

Figure 48. APAC Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)

Figure 49. APAC Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 50. China Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 51. Japan Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 52. South Korea Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 53. Southeast Asia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 54. India Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 55. Australia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 56. ChinaTaiwan Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 57. Europe Duchenne Muscular Dystrophy Sales Market Share by Country in 2025

Figure 58. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)

Figure 59. Europe Duchenne Muscular Dystrophy Sales Market Share byType (2020-2025)

Figure 60. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 61. Germany Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$

millions)

Figure 62. France Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 63. UK Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 64. Italy Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 65. Russia Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 66. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2025)

Figure 67. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)

Figure 68. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 69. Egypt Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 70. South Africa Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 71. Israel Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 72. Turkey Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 73. GCC Countries Duchenne Muscular Dystrophy Revenue Growth 2020-2025 (\$ millions)

Figure 74. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy in 2025

Figure 75. Manufacturing Process Analysis of Duchenne Muscular Dystrophy

Figure 76. Industry Chain Structure of Duchenne Muscular Dystrophy

Figure 77. Channels of Distribution

Figure 78. Global Duchenne Muscular Dystrophy Sales Market Forecast by Region (2026-2031)

Figure 79. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Region (2026-2031)

Figure 80. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Type (2026-2031)

Figure 81. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type (2026-2031)

Figure 82. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Application (2026-2031)

Figure 83. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by

Application (2026-2031)

I would like to order

Product name: Global Duchenne Muscular Dystrophy Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G64DA9E4FAAEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G64DA9E4FAAEN.html>